Novartis Japan Facing Unprecedented Business Suspension
This article was originally published in PharmAsia News
Novartis is facing the prospect of an unprecedented temporary suspension order against its business in Japan over failures to report serious side-effects with its drugs.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.